Effect of a treat-to-target strategy based on methotrexate and intra-articular betamethasone with or without additional cyclosporin on MRI-assessed synovitis, osteitis, tenosynovitis, bone erosion, and joint space narrowing in early rheumatoid arthritis: results from a 2-year randomized double-blind placebo-controlled trial (CIMESTRA)

S. Møller-Bisgaard, B. J. Ejbjerg, I. Eshed, K. Hørslev-Petersen, M. L. Hetland, A. G. Jurik, H. Thomsen, T. Torfing, K. Stengaard-Pedersen, P. Junker, N. S. Krogh, T. Lottenburger, T. Ellingsen, L. S. Andersen, H. Skjødt, A. J. Svendsen, U. Tarp, I. T. Hansen, J. Pødenphant, J. K. PedersenH. Lindegaard, Lars G. Hanson, A. Vestergaard, D. Glinatsi, M. Østergaard

Research output: Contribution to journalJournal articleResearchpeer-review

1 Downloads (Pure)

Abstract

Objectives: To investigate whether a treat-to-target strategy based on methotrexate (MTX) and intra-articular (IA) betamethasone suppresses magnetic resonance imaging (MRI)-determined measures of disease activity and reduces joint destruction in early rheumatoid arthritis (eRA) patients, and to investigate whether concomitant cyclosporin A (CyA) provides an additional effect.Method: In the 2-year randomized, double-blind, treat-to-target trial CIMESTRA, 160 patients with eRA (<6months) were randomized to MTX, intra-articular betamethasone and CyA, or placebo CyA. A total of 129 patients participated in the MRI substudy, and had contrast-enhanced MR images of the non-dominant hand at months 0, 6, 12, and 24. MR images were evaluated for osteitis, synovitis, tenosynovitis, bone erosion, and joint space narrowing (JSN), using validated scoring methods.Results: Significant reductions were seen at 6months in all inflammatory parameters [synovitis, mean change -1.6 (p
Original languageEnglish
JournalScandinavian Journal of Rheumatology
Volume46
Issue number5
Pages (from-to)335-345
ISSN0300-9742
DOIs
Publication statusPublished - 2017

Fingerprint Dive into the research topics of 'Effect of a treat-to-target strategy based on methotrexate and intra-articular betamethasone with or without additional cyclosporin on MRI-assessed synovitis, osteitis, tenosynovitis, bone erosion, and joint space narrowing in early rheumatoid arthritis: results from a 2-year randomized double-blind placebo-controlled trial (CIMESTRA)'. Together they form a unique fingerprint.

Cite this